Opill, an Over-the-Counter Birth Control Pill, Will Be Available Soonnews2024-03-04T22:59:02+00:00March 4th, 2024|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
The F.D.A. Now Says It Plainly: Morning-After Pills Are Not Abortion Pillsnews2022-12-24T01:22:45+00:00December 24th, 2022|The New York Times|
Senators Question Califf, the F.D.A. Nominee, on Opioid Crisis and Pandemic Responsenews2021-12-14T23:44:00+00:00December 14th, 2021|The New York Times|
Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drugnews2021-11-22T16:00:09+00:00November 22nd, 2021|The New York Times|
Specialty Pharmacies Cater to the Blind and Those With Impaired Visionnews2021-09-21T16:28:23+00:00September 21st, 2021|The New York Times|
How an Unproven Alzheimer’s Drug Got Approvednews2021-07-20T02:12:00+00:00July 20th, 2021|The New York Times|
In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drugnews2021-07-09T19:12:53+00:00July 9th, 2021|The New York Times|
